Evidence map›Paper›PMID 38060170›Full record

ArticleDigestive diseases and sciences2024

Limitations of Noninvasive Tests-Based Population-Level Risk Stratification Strategy for Nonalcoholic Fatty Liver Disease.

Jaideep Behari, Allison Bradley, Kevin Townsend, Michael J Becich, Nickie Cappella, Cynthia H Chuang, Soledad A Fernandez, Daniel E Ford, H Lester Kirchner, Richard Morgan and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jaideep BehariDivision of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh School of Medicine, Suite 201, Kaufmann Medical Building, 3471 Fifth Ave, Pittsburgh, PA, 15213, USA. behajx@upmc.edu.ORCID http://orcid.org/0000-0001-8077-5137
Allison BradleyDepartment of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15206, USA.
Kevin TownsendUS Medical Affairs, Pfizer Inc, New York, NY, 10017, USA.
Michael J BecichDepartment of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15206, USA.
Nickie CappellaDepartment of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15206, USA.
Cynthia H ChuangDivision of General Internal Medicine, Penn State College of Medicine, Hershey, PA, 17033, USA.
Soledad A FernandezDepartment of Biomedical Informatics, Wexner Medical Center, The Ohio State University, Columbus, OH, 43201, USA.
Daniel E FordDepartment of General Internal Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
H Lester KirchnerDepartment of Population Health Sciences, Geisinger Health System, Danville, PA, 17822, USA.
Richard MorganDepartment of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15206, USA.
Anuradha ParanjapeDepartment of Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Jonathan C SilversteinDepartment of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15206, USA.
David A WilliamsDepartment of Anesthesiology, University of Michigan, Ann Arbor, MI, 48105, USA.
W Troy DonahooDivision of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL, 32608, USA.
Sumeet K AsraniBaylor University Medical Center, Dallas, TX, 75246, USA.
Fady NtaniosUS Medical Affairs, Pfizer Inc, New York, NY, 10017, USA.
Mohammad AteyaUS Medical Affairs, Pfizer Inc, New York, NY, 10017, USA.
Rozelle Hegeman-DingleUS Medical Affairs, Pfizer Inc, New York, NY, 10017, USA.
Euan McLeodPfizer Health Economics and Outcomes Research, Tadworth, UK.
Kathleen McTigueDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15260, USA.

Funding

Novel Determinants for Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma and Other Health OutcomesR01CA255809 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BEHARI, JAIDEEP, YUAN, JIAN-MIN · 2021 to 2025
$3.7M
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver diseaseUH3TR003289 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BEHARI, JAIDEEP, SOTO-GUTIERREZ, ALEJANDRO · 2022 to 2024
$2.3M
NCATS NIH HHS 4UH3TR003289NCI NIH HHS 1R01CA255809Patient-Centered Outcomes Research Institute RI-CRN-2020-006
6 · The paper itself

Abstract

backgroundNonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are highly prevalent but underdiagnosed.

aimsWe used an electronic health record data network to test a population-level risk stratification strategy using noninvasive tests (NITs) of liver fibrosis.

methodsData were obtained from PCORnet

resultsOf 11,875,959 patients, 0.8% and 0.1% were coded with NAFLD and NASH, respectively. NAFLD diagnosis rates in White, Black, and Hispanic patients were 0.93%, 0.50%, and 1.25%, respectively, and for NASH 0.19%, 0.04%, and 0.16%, respectively. Among undiagnosed patients, insufficient EHR data for estimating NITs ranged from 68% (FIB-4) to 76% (NFS). Predicted prevalence of NAFLD by HSI was 60%, with estimated prevalence of advanced fibrosis of 13% by NFS and 7% by FIB-4. Approximately, 15% and 23% of patients were classified in the intermediate range by FIB-4 and NFS, respectively. Among NAFLD-cirrhosis patients, a third had FIB-4 scores in the low or intermediate range.

conclusionsWe identified several potential barriers to a population-level NIT-based screening strategy. HSI-based NAFLD screening appears unrealistic. Further research is needed to define merits of NFS- versus FIB-4-based strategies, which may identify different high-risk groups.

Indexed as

Non-alcoholic Fatty Liver DiseaseAgedBiopsyHumansLiverLiver CirrhosisRisk AssessmentSeverity of Illness IndexFibrosis-4 indexHepatic Steatosis IndexMetabolic dysfunction-associated steatotic liver diseaseNAFLD fibrosis scoreNAFLD screeningNonalcoholic steatohepatitis

Identifiers

PMID38060170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.